127 Potential Immunological Triggers for Central Disorders of Hypersomnolence Supplementary Table 3: Continued. Variable Narcolepsy type 1 (N = 194) Narcolepsy type 2 or idiopathic hypersomnia (N = 71) Odds ratio (95% CI) Effect size Corrected p-value Infections & influenza vaccinations N Percentage of N N Percentage of N H1N1 influenza vaccination prevalence 142 23.2% 57 3.5% 8.32 (1.93-35.98) 0.2343 0.0048# 0.5073# Other years/unspecified influenza vaccination prevalence 142 7.7% 57 12.3% 0.60 (0.22-1.63) 0.0715 0.4926 Proportion of H1N1 influenza vaccination of all influenza vaccination 44 75.0% 9 22.2% 10.50 (1.89-58.24) 0.4184 0.0213# Proportion of other years/ unspecified influenza vaccination of all influenza vaccination 44 25.0% 9 77.8% 0.10 (0.02-0.53) 0.4184 0.0213# Rapid onset after influenza vaccination 44 34.1% 9 11.1% 4.14 (0.47-36.25) 0.1879 0.4395# Rapid onset after H1N1 influenza vaccination 33 45.5% 2 50.0% 1.20 (0.07-20.85) 0.0211 1.0000# N reflects the available data for the corresponding variable. # Fisher’s exact test was performed. CI = confidence interval. 4
RkJQdWJsaXNoZXIy MjY0ODMw